Canada Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

All the vital news, analysis, and commentary curated by our industry experts.

$4995

Buy Report

Published: June 23, 2025 Report Code: GDME25628CCDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “Canada Oncology Market Outlook to 2033” is a comprehensive databook report, covering key market data on the Canada Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Canada Oncology Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for Oncology Market.
• Global corporate-level profiles of key companies operating within the Canada Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Canada Oncology is segmented as follows – _x000D_

• Colorectal Cancer Screening Tests_x000D_

• EGFR Tests_x000D_

• KRAS Tests_x000D_

• HER2 Tests_x000D_

• BRCA Tests_x000D_

• ALK Tests_x000D_

• BRAF Tests_x000D_

• BCR-ABL Tests_x000D_

• PD-L1 Tests

Reasons to Buy

The Canada Oncology Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Abbott Laboratories

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 6

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Oncology Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 9

3 Oncology Market, Canada 16

3.1 Oncology Market, Canada, Revenue ($m), 2018-2033 16

3.1.1 ALK Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 19

3.1.2 BCR-ABL Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 21

3.1.3 BRAF Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 23

3.1.4 BRCA Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 25

3.1.5 Colorectal Cancer Screening Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 27

3.1.6 EGFR Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 29

3.1.7 HER2 Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 31

3.1.8 KRAS Tests Market, Canada, Revenue ($m), by Segment, 2018-2033 33

3.2 Oncology Market, Canada, Volume (Units), 2018-2033 35

3.2.1 ALK Tests Market, Canada, Volume (Units), by Segment, 2018-2033 38

3.2.2 BCR-ABL Tests Market, Canada, Volume (Units), by Segment, 2018-2033 40

3.2.3 BRAF Tests Market, Canada, Volume (Units), by Segment, 2018-2033 42

3.2.4 BRCA Tests Market, Canada, Volume (Units), by Segment, 2018-2033 44

3.2.5 Colorectal Cancer Screening Tests Market, Canada, Volume (Units), by Segment, 2018-2033 46

3.2.6 EGFR Tests Market, Canada, Volume (Units), by Segment, 2018-2033 49

3.2.7 HER2 Tests Market, Canada, Volume (Units), by Segment, 2018-2033 51

3.2.8 KRAS Tests Market, Canada, Volume (Units), by Segment, 2018-2033 53

3.3 Oncology Market, Canada, Average Price ($) , 2018-2033 55

3.4 Oncology Market, Canada, Company Share by Revenue ($m), 2024 59

4 Overview of Key Companies in Canada, Oncology Market 61

4.1 Agilent Technologies Inc 61

4.1.1 Company Overview 61

4.2 F. Hoffmann-La Roche Ltd 61

4.2.1 Company Overview 61

4.3 Abbott Laboratories 61

4.3.1 Company Overview 61

4.4 Qiagen NV 61

4.4.1 Company Overview 61

4.5 Danaher Corp 62

4.5.1 Company Overview 62

4.6 Eiken Chemical Co Ltd 62

4.6.1 Company Overview 62

4.7 Thermo Fisher Scientific Inc 62

4.7.1 Company Overview 62

4.8 Amoy Diagnostics Co Ltd 62

4.8.1 Company Overview 62

4.9 Hemosure Inc 63

4.9.1 Company Overview 63

4.10 Quidelortho Corp 63

4.10.1 Company Overview 63

5 Oncology Market Pipeline Products 64

6 Financial Deals Landscape 128

6.1 Acquisition 128

6.1.1 Quest Diagnostics Acquires LifeLabs for USD984.2 Million 128

6.2 Equity Offerings 130

6.2.1 ProMIS Neurosciences Raises USD30.38 Million in Private Placement of Units 130

6.3 Venture Financing 132

6.3.1 Syantra Secures USD3.6 Million in Series A-1 Funding 132

7 Recent Developments 134

7.1 Corporate Communications 134

7.1.1 Feb 04, 2025: Groundbreaking Alzheimer's and Cancer Studies Receive $7.2M Boost 134

7.1.2 Jan 08, 2025: Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth and Accelerate Innovation in Long-Acting Therapies 134

7.2 Financial Announcements 135

7.2.1 Feb 05, 2025: Hologic Reports Results for Q1 of Fiscal 2025 135

7.2.2 Dec 16, 2024: StageZero Life Sciences Reports Q3 2024 Results and Operational Update 136

7.2.3 Nov 28, 2024: MedMira Reports FY2024 Fourth Quarter and Year End Financial Results 137

7.2.4 Oct 01, 2024: StageZero Life Sciences Announces Q2 2024 Financial Results and Operational Update 138

7.2.5 Jun 19, 2024: Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024 139

7.3 Government and Public Interest 139

7.3.1 Jul 13, 2024: New Analysis Examines Role of Conditional Approvals on Access to Promising Oncology Therapies 139

7.4 Other Significant Developments 140

7.4.1 Feb 27, 2025: Avitia Launches AI-Powered Platform for Rapid & Point-Of-Care Cancer Testing 140

7.4.2 Nov 29, 2024: Government of Canada Invests in Breast Cancer Research and Public Awareness 140

7.4.3 Nov 14, 2024: Brain Tumor Funders' Collaborative Announces New Grant Opportunity to Support Studies on Liquid Biopsy in Primary Brain Tumors 141

7.4.4 Aug 19, 2024: ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology 142

7.5 Product News 142

7.5.1 May 13, 2025: Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025 142

7.5.2 May 05, 2025: Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025 144

7.5.3 Mar 24, 2025: Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting 145

7.5.4 Nov 21, 2024: Bostongene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2024 Annual Meeting 145

7.5.5 Nov 14, 2024: New Microfluidic Device Reveals How the Shape of a Tumour Can Predict a Cancer’s Aggressiveness 146

7.5.6 Oct 23, 2024: Lung Health Foundation: New Evict Radon National Study Report Underscores ‘Urgent Need for Canada-Wide Advocacy’ to Reduce Dangerous Radon Levels in Canadian Homes 147

7.5.7 Oct 01, 2024: PocketHealth Launches New Breast Health Tools to Help Detect Breast Cancer Earlier 148

7.5.8 Jun 26, 2024: Scientists discover high-risk form of endometrial cancer — and how to test for it — using AI 148

7.5.9 Jun 12, 2024: 'Precision Medicine is Transforming Cancer Care' – Colorectal Cancer Resource & Action Network (CCRAN) Announces Second Annual Pan-Tumor Biomarkers Conference 149

7.6 Strategy And Business Planning 150

7.6.1 Nov 08, 2024: Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment 150

7.6.2 Oct 16, 2024: Cervical and Lung Cancer Screening Programs Expanding and Innovating Across Canada, Canadian Partnership Against Cancer's New Reports Show 150

7.6.3 Sep 16, 2024: New Collaboration to Introduce Liquid Biopsy Testing for Lung Cancer 151

7.6.4 Sep 04, 2024: Semaphore Solutions Announces Expansion of Partnership With BillionToOne 152

8 Appendix 153

8.1 Research Methodology 154

8.1.1 Coverage 154

8.1.2 Secondary Research 154

8.1.3 Primary Research 154

8.1.4 Market Modeling and Forecasting 155

8.1.5 Company Share Analysis 156

8.1.6 Benchmarking 157

8.2 GlobalData Consulting 158

8.3 Contact Us 158

8.4 Disclaimer 158

Table

Table 1: Oncology Market, Canada, Revenue ($m), USD Constant, 2018-2033 17

Table 2: ALK Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 20

Table 3: BCR-ABL Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 22

Table 4: BRAF Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 24

Table 5: BRCA Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 26

Table 6: Colorectal Cancer Screening Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 28

Table 7: EGFR Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 30

Table 8: HER2 Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 32

Table 9: KRAS Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 34

Table 10: Oncology Market, Canada, Volume (Units), 2018-2033 36

Table 11: ALK Tests Market, Canada, Volume (Units), 2018-2033 39

Table 12: BCR-ABL Tests Market, Canada, Volume (Units), 2018-2033 41

Table 13: BRAF Tests Market, Canada, Volume (Units), 2018-2033 43

Table 14: BRCA Tests Market, Canada, Volume (Units), 2018-2033 45

Table 15: Colorectal Cancer Screening Tests Market, Canada, Volume (Units), 2018-2033 47

Table 16: EGFR Tests Market, Canada, Volume (Units), 2018-2033 50

Table 17: HER2 Tests Market, Canada, Volume (Units), 2018-2033 52

Table 18: KRAS Tests Market, Canada, Volume (Units), 2018-2033 54

Table 19: Oncology Market, Canada, Average Price ($), 2018-2033 55

Table 20: Oncology Market, Canada, Company Share by Revenue ($m), 2024 60

Table 21: Oncology Market Pipeline Products 64

Table 22: Quest Diagnostics Acquires LifeLabs for USD984.2 Million 128

Table 23: ProMIS Neurosciences Raises USD30.38 Million in Private Placement of Units 130

Table 24: Syantra Secures USD3.6 Million in Series A-1 Funding 132

Table 25: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 155

Figures

Figure 1: Oncology Market, Canada, Revenue ($m), USD Constant, 2018-2033 16

Figure 2: ALK Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 19

Figure 3: BCR-ABL Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 21

Figure 4: BRAF Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 23

Figure 5: BRCA Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 25

Figure 6: Colorectal Cancer Screening Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 27

Figure 7: EGFR Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 29

Figure 8: HER2 Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 31

Figure 9: KRAS Tests Market, Canada, Revenue ($m), USD Constant, 2018-2033 33

Figure 10: Oncology Market, Canada, Volume (Units), 2018-2033 35

Figure 11: ALK Tests Market, Canada, Volume (Units), 2018-2033 38

Figure 12: BCR-ABL Tests Market, Canada, Volume (Units), 2018-2033 40

Figure 13: BRAF Tests Market, Canada, Volume (Units), 2018-2033 42

Figure 14: BRCA Tests Market, Canada, Volume (Units), 2018-2033 44

Figure 15: Colorectal Cancer Screening Tests Market, Canada, Volume (Units), 2018-2033 46

Figure 16: EGFR Tests Market, Canada, Volume (Units), 2018-2033 49

Figure 17: HER2 Tests Market, Canada, Volume (Units), 2018-2033 51

Figure 18: KRAS Tests Market, Canada, Volume (Units), 2018-2033 53

Figure 19: Oncology Market, Canada, Company Share (%), 2024 59

Canada Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others standard reports

Currency USD

Single User

$4,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Global M&A Deals in H1 2026 - Top Themes by…

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Canada Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others in real time.

Access a live Canada Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Canada Oncology Market Outlook to 2033: Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports